BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) is a publicly traded the market company. As of May 21, 2026, BBOT trades at $8.63 with a market cap of $700.94M and a P/E ratio of -0.02. BBOT moved +0.92% today. Year to date, BBOT is -22.31%; over the trailing twelve months it is flat. Its 52-week range spans $7.60 to $14.87. Analyst consensus is strong buy with an average price target of $24.06. Rallies surfaces BBOT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own BBOT include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BridgeBio Oncology Therapeutics, Inc. Common Stock.
| Metric | Value |
|---|---|
| Price | $8.63 |
| Market Cap | $700.94M |
| P/E Ratio | -0.02 |
| EPS | $-476.18 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.87 |
| 52-Week Low | $7.60 |
| Volume | 300 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.16K |
| Net Income | $-154.09M |
| Gross Margin | 0.00% |
8 analysts cover BBOT: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.06.